145P Preliminary results of a phase Ⅱ study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC)

Y Shu,P Ma,H Shen,W Gao,X Chen,J Sun,L Xu

doi:10.1016/j.iotech.2022.100257

145P Preliminary results of a phase Ⅱ study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC)

Y Shu, P Ma + Show 5 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100257

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
License type: cc-by-nc-nd

Affiliation: Jiangsu Province Hospital

#Non-squamous Non-small Cell Lung Cancer #Advanced EGFR + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Fruquintinib(F) is an orally available VEGFR inhibitor that is highly selective for VEGFR-1,2 and 3. In the phase Ⅱ and Ⅲ trials, F has been shown an improved progression-free survival(PFS) compared to placebo and a manageable safety profile with advanced NSCLC. This study aimed to investigate the efficacy and safety of F plus PD-1 inhibitor sintilimab(S) and platinum-based chemotherapy(chemo) as the first-line treatment for advanced naive EGFR- and ALK-negative nsq-NSCLC.

Full Text